Key Takeaways

核心要点

Combined with its Seed round of $8.5M, the company has

加上其850万美元的种子轮融资，该公司已

raised more than $16.5M

筹集超过1650万美元

in support of its activities.

以支持其活动。

Vinci Pharmaceuticals

文奇制药

closed an $8+ million Series A financing

完成超800万美元的A轮融资

round to support manufacturing, testing/release activities and first-in-human studies of its EPIPLANT™ drug delivery platform.

本轮融资旨在支持其EPIPLANT™药物递送平台的制造、测试/放行活动以及首次人体研究。

EPIPLANT™, the company's

EPIPLANT™，该公司的

proprietary, episcleral sustained-release drug delivery platform

专有巩膜上缓释药物递送平台

is designed to address limitations of intraocular injections.

旨在解决眼内注射的局限性。

A

A

Phase 1/2a

1/2a期

clinical study is scheduled

临床研究已安排

for 2027.

2027年。

AVON-BY-THE-SEA, N.J.

新泽西州海滨阿文

,

，

Oct. 8, 2026

2026年10月8日

/PRNewswire/ -- Vinci Pharmaceuticals Inc., a specialty ophthalmic pharmaceutical company, has closed an $8+ million Series A financing round as the company advances development of its innovative EPIPLANT™ delivery platform. Previously, the company raised $8.5M, excluding interest on convertible notes, in Seed Stage financing, for a total of more than $16.5M..

/美通社/ -- 专业眼科制药公司Vinci Pharmaceuticals Inc.已完成超过800万美元的A轮融资，以推进其创新EPIPLANT™给药平台的开发。此前，该公司在种子轮融资中筹集了850万美元（不含可转换票据利息），融资总额已超过1,650万美元。

Developed in the laboratory of Karl Csaky, MD, PhD, and licensed from the Retina Foundation of the Southwest in Dallas, Texas, EPIPLANT™ is a proprietary episcleral implant platform designed to provide sustained drug delivery to retinal tissues and address limitations associated with intraocular injections.

EPIPLANT™ 由 Karl Csaky 医学博士、哲学博士的实验室开发，并从位于德克萨斯州达拉斯的西南视网膜基金会获得许可，是一种专有的巩膜外植入平台，旨在为视网膜组织提供持续的药物递送，并克服与眼内注射相关的局限性。

Vinci is advancing the program with guidance from its scientific advisory board of physicians..

Vinci 在其由医生组成的科学顾问委员会的指导下，正在推进该计划。

The financing was led by Dynagrow Capital, LLLP, with support from MintPharma Capital. Proceeds from the financing are expected to support GMP manufacturing, testing and release activities of the EPIPLANT™ VCI-002 product, and the Phase 1/2a study in 2027.

本轮融资由Dynagrow Capital, LLLP领投，MintPharma Capital提供支持。融资所得预计将用于支持EPIPLANT™ VCI-002产品的GMP生产、检测与放行活动，以及2027年开展的1/2a期临床研究。

'We are grateful for the support and confidence of our investors and board, who recognize the potential of our EPIPLANT™ delivery system to transform the treatment of sight-threatening diseases and address unmet needs in the field,' said Philip A. Gioia, Co-founder, Chairman and Chief Executive Officer of Vinci Pharmaceuticals.

“我们感谢投资者和董事会的支持与信任，他们认可我们的EPIPLANT™递送系统在改变威胁视力疾病的治疗方式以及满足该领域未竟需求方面的潜力，”Vinci Pharmaceuticals的联合创始人、董事长兼首席执行官Philip A. Gioia表示。

'This financing supports an important next step: preparing for our first-in-human study. We believe EPIPLANT™ has the potential to provide safe sustained drug delivery to retinal tissues and reduce treatment burden for patients and physicians.'.

“此次融资支持一个重要的下一步：为我们的人体首次研究做准备。我们相信 EPIPLANT™ 有潜力为视网膜组织提供安全的持续药物递送，并减轻患者和医生的治疗负担。”

Sarah Hassan, Managing Director at Dynagrow Capital added, 'Vinci's EPIPLANT represents a potential paradigm shift for eye doctors and their patients facing retinal disease challenges. This potential multi-molecule platform technology involving a needle-free delivery system for small molecules could dramatically increase adherence time for patients presently experiencing an unacceptably high dropout rate due to treatment burden.

Dynagrow Capital 的执行董事 Sarah Hassan 补充道：“Vinci 公司的 EPIPLANT 代表了眼科医生及其面临视网膜疾病挑战的患者的一种潜在范式转变。这种涉及小分子无针递送系统的潜在多分子平台技术，可以显著提高患者的依从性时长；目前，由于治疗负担过重，患者流失率高得令人难以接受。”

We are happy to partner with Vinci's talented team and support them in this most pivotal time advancing EPIPLANT VCI-002 to patients.'.

我们很高兴与Vinci才华横溢的团队建立合作伙伴关系，并在这一将EPIPLANT VCI-002推进至患者手中的最关键时期为他们提供支持。

The company has been granted multiple patents covering its proprietary EPIPLANT™ technology and has completed preliminary preclinical testing. Vinci plans to initiate a first-in-human Phase 1/2a clinical study in 2027.

该公司已就其专有的EPIPLANT™技术获得多项专利，并完成了初步的临床前测试。Vinci计划于2027年启动首次人体I/IIa期临床研究。

Existing drug delivery approaches for retinal diseases often require administration directly into the eye or face challenges in achieving effective drug concentrations in retinal tissues. EPIPLANT™ is designed to address these limitations through sustained drug delivery from an episcleral implant. The bioerodible platform is designed to accommodate a range of active pharmaceutical ingredients, with the potential to support multiple therapies for retinal diseases..

现有的视网膜疾病药物递送方法通常需要将药物直接注入眼内，或在实现视网膜组织有效药物浓度方面面临挑战。EPIPLANT™ 旨在通过巩膜外植入物的持续药物递送来克服这些局限性。该生物可侵蚀平台设计用于容纳多种活性药物成分，有望支持针对视网膜疾病的多种疗法。

'EPIPLANT™ delivers targeted drug levels to the macula, making it a more desirable option for treating certain ophthalmic diseases of the retina compared to intravitreal injections, the current standard of care,' said Richard Lindstrom, MD, of Minnesota Eye Consultants. 'The EPIPLANT™ technology also opens the door to novel therapies for retinal indications that are currently untreated.'.

明尼苏达眼科顾问公司的理查德·林德斯特伦医学博士表示：“EPIPLANT™ 能够将药物精准递送至黄斑区，使其成为治疗某些视网膜眼科疾病的更理想选择，优于当前的标准疗法——玻璃体腔注射。此外，EPIPLANT™ 技术也为目前尚无有效治疗手段的视网膜适应症开辟了新型疗法的可能性。”

Vinci Pharmaceuticals plans one Phase 1/2a clinical trial of its EPIPLANT™ episcleral sustained-release delivery system in 2027. Currently the system can deliver small molecules, allowing for broad application for multiple retinal diseases.

Vinci Pharmaceuticals 计划于 2027 年对其 EPIPLANT™ 巩膜上缓释给药系统开展一项 I/IIa 期临床试验。目前，该系统能够递送小分子药物，从而为多种视网膜疾病的广泛应用提供了可能。

About Vinci Pharmaceuticals

关于文奇制药

Vinci Pharmaceuticals Inc. is a clinic ready ophthalmic company that is leveraging a novel, proprietary platform to develop first-, best- and only-in-class products with differentiated profiles to treat certain diseases of the retina.

Vinci Pharmaceuticals Inc. 是一家具备临床开发条件的眼科公司，正利用其新颖的专有平台，开发具有差异化特征的同类首创、同类最优及同类唯一产品，用于治疗某些视网膜疾病。

Safe Harbor

安全港

This press release contains forward-looking statements, which include information relating to future events, future financial performance, financial projections, strategies, expectations, competitive environment and regulations. Forward-looking statements should not be read as a guarantee of future performance or results and may not be accurate indications of when such performance or results will be achieved.  Forward-looking statements are based on information Vinci Pharmaceuticals has when those statements are made or management's good faith belief as of that time with respect to future events and are subject to risks and uncertainties that could cause actual performance or results to differ materially from those expressed in or suggested by the forward-looking statements..

本新闻稿包含前瞻性陈述，其中包括与未来事件、未来财务表现、财务预测、战略、预期、竞争环境和法规相关的信息。前瞻性陈述不应被视为对未来表现或结果的保证，也可能无法准确指示何时能实现此类表现或结果。前瞻性陈述基于Vinci Pharmaceuticals在作出这些陈述时所掌握的信息，或管理层在当时对未来事件的善意信念，并受风险和不确定性的影响，这些风险和不确定性可能导致实际表现或结果与前瞻性陈述中表达或暗示的内容存在重大差异。

Contact

联系

Vinci Pharmaceuticals Inc.

文奇制药公司

Phil Gioia

菲尔·吉奥亚

Co-Founder, Chairman & CEO

联合创始人、董事长兼首席执行官

Email:

电子邮件：

[email protected]

[email protected]

SOURCE Vinci Pharmaceuticals

来源：Vinci Pharmaceuticals

21

二十一

%

%

more press release views with

更多新闻稿浏览量，通过

Request a Demo

申请演示